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ABSTRACT	1 
Effective	 diabetic	 kidney	 disease	 (DKD)	 biomarkers	 remain	 elusive,	 and	 urinary	2 
microRNAs	 (miRNAs)	 represent	 a	 potential	 source	 of	 novel	 non-invasive	 disease	3 
sentinels.	We	profiled	754	miRNAs	in	pooled	urine	samples	from	DKD	patients	(n	=	20),	4 
detecting	significantly	increased	miR-126,	miR-155	and	miR-29b	compared	to	controls	5 
(n	=	20).	These	results	were	confirmed	in	an	 independent	cohort	of	89	DKD	patients,	6 
62	 diabetic	 patients	 without	 DKD	 and	 41	 controls:	 miR-126	 (2.8-fold	 increase;	7 
p<0.0001),	miR-155	 (1.8-fold;	 p<0.001)	 and	miR-29b	 (4.6-fold;	 p	 =	 0.024).	 Combined	8 
receiver	operating	characteristic	curve	analysis	resulted	in	an	area	under	the	curve	of	9 
0.8.	A	 relative	quantification	 threshold	 equivalent	 to	 80%	 sensitivity	 for	 each	miRNA	10 
gave	a	positive	signal	for	48%	of	DKD	patients	compared	to	3.6%	of	diabetic	patients	11 
without	 DKD.	 Laser	 capture	 microdissection	 of	 renal	 biopsies	 followed	 by	 RT-qPCR	12 
detected	miR-155	 in	 glomeruli,	 proximal	 and	 distal	 tubules,	while	miR-126	 and	miR-13 
29b	 were	 most	 abundant	 in	 glomerular	 extracts.	 Subsequent	 experiments	 showed	14 
miR-126	and	miR-29b	enrichment	in	glomerular	endothelial	cells	(GEnCs)	compared	to	15 
podocytes,	proximal	tubular	epithelial	cells	and	fibroblasts.	Significantly	increased	miR-16 
126	and	miR-29b	were	detected	in	GEnC	conditioned	medium	in	response	to	tumour	17 
necrosis	 factor-alpha	 and	 transforming	 growth	 factor-beta	 1,	 respectively.	 Our	 data	18 
reveal	an	altered	urinary	miRNA	profile	associated	with	DKD	and	link	these	variations	19 
to	miRNA	release	from	GEnCs.	20 
	21 
Keywords:	 microRNAs,	 urine,	 biomarker,	 diabetic	 kidney	 disease,	 chronic	 kidney	22 
disease	23 
	 	24 
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Abbreviations:		25 
ACR	 	 albumin:creatinine	ratio	26 
CKD	 	 chronic	kidney	disease	27 
DKD	 	 diabetic	kidney	disease	28 
eGFR	 	 estimated	glomerular	filtration	rate	29 
GEnC	 	 glomerular	endothelial	cell	30 
KDIGO		 kidney	disease:	improving	global	outcomes	31 
NKF	KDOQI	 National	Kidney	Foundation	kidney	disease	outcomes	quality	initiative	32 
LCM	 	 laser	capture	microdissection	33 
MDRD	 	 modification	of	diet	in	renal	disease	34 
miRNA		 microRNA	35 
PTC	 	 proximal	tubular	epithelial	cell	36 
RIISC	 	 renal	impairment	in	secondary	care	study	37 
	38 
	 	39 
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Introduction	40 
Recent	estimates	suggest	that	1	in	12	of	the	global	population	suffers	from	diabetes	41 
mellitus,	approximately	40	%	of	those	affected	will	go	on	to	develop	diabetic	kidney	42 
disease	(DKD).1	DKD	is	the	leading	cause	of	end-stage	renal	disease	and	predisposing	43 
factors	 include	 genetic	 causes,	 ethnicity,	 hyperglycaemia,	 insulin	 resistance,	44 
intraglomerular	hypertension	and	hyperfiltration.2,3	45 
	 Hyperglycaemia	 results	 in	 numerous	 deleterious	 consequences	 including	46 
upregulated	 cytokine	 synthesis,	 renin-angiotensin	 system	 activation,	 generation	 of	47 
advanced	glycation	end	products	and	reactive	oxygen	species,	and	increased	protein	48 
kinase	 C	 activity.4,5	 Nitric	 oxide	 and	NF-κB	 pathway-driven	 loss	 of	 endothelial	 and	49 
vascular	modulation	have	been	 implicated	 in	 insulin	resistance,	and	early	DKD	may	50 
be	associated	with	 insulin	signaling	defects	 specific	 to	 the	podocyte.6	These	 insults	51 
result	 in	 loss	 of	 glomerular	 filtration	 rate	 and	 ultimately	 to	 renal	 failure	 from	52 
mesangial	 hyperexpansion,	 nodular	 glomerulosclerosis	 and	 tubulointerstitial	53 
fibrosis.7	54 
	 Detection	 of	 urinary	 microalbuminuria	 currently	 forms	 the	 basis	 of	 DKD	55 
progression	monitoring,	 varying	 from	 normal	mean	 albuminuria	 values	 around	 10	56 
mg/day	to	a	diagnosis	of	microalbuminuria	at	30–300	mg/day	and	macroalbuminuria	57 
above	 300	 mg/day.8	 Prognosis	 is	 complicated,	 since	 not	 all	 microalbuminuric	58 
patients	progress	 to	overt	nephropathy.	A	number	of	novel	biomarkers	have	been	59 
assessed	for	utility	 in	DKD	but	none	are	being	used	as	routine	clinical	markers,	and	60 
they	may	lack	specificity	and	sensitivity	to	predict	individual	DKD	patient	outcomes.	61 
In	 light	 of	 the	 above,	 novel	 markers	 that	 can	 discriminate	 aetiology,	 progression	62 
and/or	response	to	treatment	remain	highly	desirable.	63 
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	 MicroRNAs	 (miRNAs)	are	ubiquitously-expressed	short	noncoding	RNAs	that	64 
regulate	 the	 expression	 of	most	 protein	 coding	 genes	 in	 the	 human	 genome,	 and	65 
detection	of	miR-192,	miR-194,	miR-215,	miR-216,	miR-146a,	miR-204	and	miR-886	66 
is	elevated	in	the	kidney.9	Urinary	miRNAs	represent	a	highly	promising	novel	source	67 
of	 non-invasive	 biomarkers	 that	 are	 stabilised	 via	 argonaute	 2	 protein/exosome	68 
association	and	are	rapidly	and	precisely	detected	by	RT-qPCR.10	69 
	 Reports	 have	 suggested	 a	 role	 for	 miRNAs	 in	 the	 pathology	 of	 DKD,11,12	70 
including	previous	work	from	this	laboratory	showing	decreased	miR-192	in	biopsies	71 
from	 late-stage	 DKD	 patients	 with	 diminished	 renal	 function.13	 However,	72 
comparatively	 little	 is	 known	 about	 the	 abundance	 of	 urinary	 miRNAs	 in	 DKD	73 
patients.	74 
	 We	 hypothesised	 that	 alterations	 in	 urinary	 miRNA	 profiles	 would	 be	75 
associated	with	DKD.	We	identified	candidate	DKD	biomarkers	by	comparing	miRNA	76 
profiles	in	urine	samples	from	a	patient	discovery	cohort	with	those	from	unaffected	77 
controls.	Selected	candidates	were	then	measured	 in	a	 larger,	 independent	cohort.	78 
Subsequently,	laser	capture	microdissection	of	renal	biopsies	and	in	vitro	cell	culture	79 
were	 used	 to	 investigate	 the	 sources	 of	 our	 candidate	 urinary	 miRNA	 DKD	80 
biomarkers	with	respect	to	nephron	domain	and	cell	type.	81 
	 	82 
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Materials	and	Methods	83 
Study	Participants	84 
DKD	was	defined	in	accordance	with	the	National	Kidney	Foundation	Kidney	Disease	85 
Outcomes	 Quality	 Initiative	 (NKF	 KDOQI)	 Clinical	 Practice	 Guidelines	 and	 Clinical	86 
Practice	 Recommendations	 for	 Diabetes	 and	 Chronic	 Kidney	 Disease	 (CKD).14	87 
Accordingly,	 CKD	 should	 be	 attributable	 to	 diabetes	 in	 the	 presence	 of	88 
macroalbuminuria	 (in	 the	 absence	 of	 urinary	 infection),	 or	 in	 the	 presence	 of	89 
microalbuminuria	with	concomitant	diabetic	retinopathy,	or	in	type	1	diabetes	of	at	90 
least	10	years	duration.14	The	initial	profiling	study	cohort	of	20	DKD	patients	and	20	91 
healthy	 controls	 was	 obtained	 from	 the	 Wales	 Kidney	 Research	 Tissue	 Bank,	92 
University	Hospital	of	Wales,	Cardiff.	The	DKD	group	was	predominantly	male	(85%),	93 
mean	age	72	years	(SD	+/-	8.7).	DKD	patients	were	CKD	stage	3-5	(pre-dialysis),	with	94 
mean	eGFR	of	29	ml/min/1.73m2	(SD	+/-	8.5)	and	a	mean	urinary	Albumin:Creatinine	95 
ratio	(ACR)	of	13.5	mg/mmol	(SD	+/-	14.5).	The	control	group	(n	=	20)	in	the	profiling	96 
cohort	were	50%	male,	mean	age	47	years	 (SD	+/-	11.0)	with	no	microalbuminuria	97 
(ACR<3	mg/mmol).	For	further	details	on	ACR	categories	see	Table	1.	98 
	99 
The	 confirmation	 cohort	was	 drawn	 from	 two	 secondary	 care	 facilities:	 the	Wales	100 
Kidney	Research	Tissue	Bank	(as	above)	and	the	Renal	Impairment	In	Secondary	Care	101 
(RIISC)	 study,	 University	 Hospital	 of	 Birmingham,	 UK.15	 	 89	 patients	 with	 DKD,	102 
including	 3	 patients	 with	 type	 1	 diabetes,	 and	 41	 healthy	 controls	 were	 recruited	103 
across	the	two	sites.	An	additional	control	group	of	62	diabetics	without	DKD	were	104 
recruited	from	Cardiff,	 including	17	patients	with	type	1	diabetes.	 	Ethical	approval	105 
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was	granted	by	the	Wales	Kidney	Research	Tissue	Bank	Governance	Committee	and	106 
the	South	Birmingham	Local	Research	Ethics	Committee,	respectively.	107 
	108 
Patient	 demographics	 and	 clinical	 parameters	 are	 shown	 in	 Table	 1.	 	 All	 patients	109 
were	recruited	from	specialist	nephrology	and	diabetes	care	services	at	the	two	sites	110 
during	 the	 period	 spanning	 autumn	2010	 to	 autumn	2013.	DKD	patients	 from	 the	111 
RIISC	study	cohort	were	predominantly	advanced	nephropaths	as	per	RIISC	protocol	112 
inclusion	criteria:	briefly,	patients	with	CKD	stages	4-5	(pre-dialysis),	or	CKD	stage	3	113 
and	 accelerated	 progression	 and/or	 proteinuria	 as	 defined	 by	 the	 UK	 National	114 
Institute	 for	 Health	 and	 Care	 Excellence	 2008	 CKD	 guideline	 for	 secondary	 care	115 
review.	The	diabetic	patient	control	group	all	had	a	diagnosis	of	diabetes	by	standard	116 
American	 Diabetes	 Association	 criteria,16	 but	 without	 evidence	 of	 DKD	 (i.e.	 not	117 
fulfilling	the	KDOQI	criteria).		118 
	119 
	At	 initial	 clinic	 visit,	 renal	 function	 was	 recorded	 using	 estimated	 glomerular	120 
filtration	 rate	 (eGFR),	 calculated	 using	 the	 modification	 of	 diet	 in	 renal	 disease	121 
(MDRD)	equation17.	Urine	samples	were	aliquoted	for	albumin:creatinine	ratio	(ACR)	122 
assessment	 and	 for	 RNA	 extraction	 (see	 below).	 ACR	 cut-offs	 for	 disease	 severity	123 
were	 defined	 as	 per	 Kidney	 Disease:	 Improving	 Global	 Outcomes	 (KDIGO)	 2012	124 
guidelines.18	125 
	126 
Urine	Collection,	RNA	Isolation	and	RT-qPCR	analysis	127 
Urine	samples	were	collected	and	RNA	extraction	from	350	µl	of	urine,	generation	of	128 
cDNA	 from	 equal	 volumes	 of	 RNA	 extracts	 and	 RT-qPCR	were	 then	 carried	 out	 as	129 
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described	 in	 detail	 elsewhere.10	 TaqMan	 assays	 (Thermo	 Fisher	 Scientific,	 Paisley,	130 
UK)	 used	 in	 this	 study	 were:	 hsa-miR-29b-3p	 (ID	 000413);	 hsa-miR-126-3p	 (ID	131 
002228);	 hsa-miR-155-5p	 (ID	 002623);	 hsa-miR-191-5p	 (ID	 002299).	 Relative	132 
quantities	 were	 calculated	 using	 the	 2-ΔΔCt	 method,	 and	 miRNA	 expression	 was	133 
normalized	to	hsa-miR-191-5p.10	134 
	135 
MiRNA	profiling	by	TaqManArray	Human	MicroRNA	Cards		136 
Urinary	miRNAs	were	reverse	transcribed	using	the	Megaplex	Primer	Pools	(Human	137 
Pools	 A	 v2.1	 and	 B	 v3.0,	 Thermo	 Fisher	 Scientific)	 with	 a	 predefined	 pool	 of	 381	138 
reverse	transcription	(RT)	primers	for	each	Megaplex	Primer	Pool.	A	fixed	volume	of	139 
3	μl	of	RNA	solution	was	used	as	 input	 in	each	RT	reaction,	and	RT	reactions	were	140 
performed	according	to	the	manufacturer’s	recommendations.	RT	reaction	products	141 
were	amplified	using	Megaplex	PreAmp	Primers	(Primers	A	v2.1	and	B	v3.0,	Thermo	142 
Fisher	 Scientific),	 the	 samples	 were	 then	 diluted	 to	 a	 final	 volume	 of	 100	 μl	 and	143 
control	subject	and	DKD	patient	products	were	pooled	as	follows.	144 
	145 
To	exclude	the	possibility	that	gender,	age	and	eGFR	status	had	extreme	effects	on	146 
miRNA	expression	profiles,	the	following	pooling	strategy	was	followed.	Control	pool	147 
(CP)1:	urine	samples	from	5	females	of	average	age	44.8	years;	CP2:	5	females,	57.6;	148 
CP3:	 5	 males,	 35.2;	 CP4,	 5	 males,	 53.2.	 Patient	 Pool	 (PP)1:	 urine	 samples	 from	 5	149 
CKD3	patients	with	an	eGFR	between	43.3	and	36	mL/min	per	1.73m2;	PP2:	5	stage	3	150 
patients,	35	-	31;	PP3:	5	stage	4/5	patients,	27.3	-	23;	PP4:	5	stage	4/5	patients,	22	-	151 
12.9.	152 
	153 
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TaqManArray	Human	MicroRNA	Cards	A	v2.1	and	B	v3.0	 (Thermo	Fisher	Scientific)	154 
were	used	to	quantify	754	human	miRNAs.	Each	array	included	377	test	miRNAs,	3	155 
endogenous	controls	and	a	negative	control.	Quantitative	(q)PCR	was	carried	out	on	156 
an	 Applied	 Biosystems	 7900HT	 thermo	 cycler	 (Thermo	 Fisher	 Scientific)	 using	 the	157 
manufacturer’s	recommended	program.	158 
	159 
Laser	Capture	Microdissection	(LCM)	from	Renal	Biopsy	Samples	160 
Glomeruli,	proximal	tubular	and	distal	tubular	profiles	were	microdissected	from	6-161 
μm	sections	obtained	from	five	FFPE	archived	renal	biopsies	from	unaffected	people	162 
using	 the	 Arcturus	 Pixcell	 IIe	 infrared	 laser	 enabled	 LCM	 system	 (Thermo	 Fisher	163 
Scientific).	164 
	165 
Cell	Culture	166 
Human	 conditionally	 immortalised	 glomerular	 endothelial	 cell	 (GEnC)	 and	 human	167 
podocyte	(ATC)	cell	lines	were	propagated	at	33°C	as	described	previously.19,20	After	168 
5	(GEnC)	and	14	(ATC)	days,	cells	were	transferred	to	37°C	 incubation	to	 inactivate	169 
the	 SV40	 T	 antigen	 and	 permit	 differentiation,	 prior	 to	 experimental	 use.	 Where	170 
stated,	 GEnCs	 were	 growth	 arrested	 for	 24	 h	 and	 then	 treated	 with	 TNF-α	 (10	171 
ng/mL)	or	TGF-β1	(1	ng/mL)	at	either	normoglycaemic	(5	mM)	or	hyperglycaemic	(25	172 
mM)	D-glucose	concentrations	for	24	h.	Proximal	tubular	epithelial	cell	(PTC)	line	HK-173 
221	 and	 fibroblast22	 cultures	 were	 maintained	 as	 described	 elsewhere.	 Cells	 and	174 
culture	medium	obtained	from	each	well	were	used	for	RNA	extraction	as	described	175 
above.	176 
	177 
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Statistical	analysis	178 
MiRNA	 profiling	 data	 were	 analysed	 using	 Thermo	 Fisher	 Scientific’s	 DataAssist	179 
Software	 (version	 3.01),	 NormFinder	 Software	 (http://moma.dk/normfinder-180 
software;	 last	 access	 21/02/18)	 and	 GraphPad	 Prism	 6	 (version	 6.0d).	 Pearson	181 
Correlation	Coefficients	was	used	to	detect	clusters	of	similarity	in	miRNA	threshold	182 
cycle	values	between	each	pool	group	in	patients,	and	between	each	pool	group	in	183 
controls.	 To	 identify	 a	 suitable	 reference	 gene	 for	 the	 normalization	 of	 miRNA	184 
expression	 in	 this	 study,	 the	 NormFinder	 algorithm	was	 applied	 to	 the	 expression	185 
data	obtained	 from	 the	Human	TaqMan	miRNA	Arrays.	Analysis	 comparing	miRNA	186 
levels	between	subjects	with	DKD	and	controls	was	carried	out	using	GraphPad	Prism	187 
version	 6	 version	 6.0d.	 Values	 for	 p	 below	 0.05	 were	 considered	 statistically	188 
significant.	 MiRNA	 profiling	 data	 sets	 can	 be	 found	 in	 Gene	 Expression	 Omnibus	189 
(https://www.ncbi.nlm.nih.gov/geo;	accession	number	GSE114477). 190 
	 	191 
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Results	192 
Altered	urinary	miRNA	detection	in	DKD	patients	193 
To	select	candidate	miRNAs	that	may	act	as	DKD	biomarkers,	we	first	compared	data	194 
from	 unbiased	 expression	 profiling	 of	 754	miRNAs	 in	 urine	 samples	 from	 20	 DKD	195 
patients	 and	20	unaffected	 controls.	 Analyses	were	performed	on	4	 patient	 and	4	196 
control	pools,	each	composed	of	urine	samples	from	5	individuals	as	recommended	197 
by	Zhang	and	colleagues.23	Samples	were	pooled	prior	 to	profiling	 to	minimize	 the	198 
contribution	of	subject	to	subject	variation	and	to	make	substantive	features	easier	199 
to	 find,	 and	 thereby	 identify	 biomarkers	 common	 across	 individuals.24	 Previous	200 
analysis	 suggested	 that	40	 individuals	might	optimally	be	pooled	across	8	arrays,23	201 
which	was	our	chosen	pooling	approach.	202 
	 In	 Figure	 1A	 the	 12	 data	 points	 in	 the	 upper	 right	 quadrant	 of	 the	 plot	203 
represent	those	miRNAs	for	which	statistically	significant	fold-change	increases	were	204 
detected	 in	patient	urine	compared	to	control	 samples,	 the	35	points	 in	 the	upper	205 
left	 quadrant	 the	 corresponding	 downregulated	miRNAs.	 The	 fold-change	 data	 for	206 
these	47	miRNAs	are	summarised	in	Figure	1B,	and	the	8	miRNAs	exhibiting	>5-fold	207 
change	 were	 subsequently	 selected	 as	 potential	 candidate	 biomarkers	 for	 further	208 
analysis.		209 
	 Specific	 RT-qPCR	 assays	 were	 then	 used	 to	 analyse	 these	 miRNAs	 in	 each	210 
component	 urine	 sample	 pooled	 for	 profiling	 analysis.	 Statistically	 significant	211 
differences	 in	 miRNA	 detection	 between	 DKD	 patient	 and	 control	 urine	 samples	212 
were	replicated	for	miR-126	(4.3-fold	 increase;	p	=	0.0087),	miR-155	(22.9-fold;	p	=	213 
0.0024)		and	miR-29b	(4.9-fold;	p	=	0.0002)	(Figure	1,	C-E).	214 
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Elevated	urinary	miR-126,	miR-155	and	miR-29b	detection	in	an	independent	DKD	215 
patient	cohort	216 
To	 test	 the	 above	 findings,	 miR-126,	 miR-155	 and	 miR-29b	 were	 quantified	 in	217 
samples	 from	 an	 independent	 cohort	 of	 patients	 with	 established	 DKD	 from	 the	218 
Renal	 Impairment	 in	 Secondary	 Care	 Study	 (RIISC).15	 Samples	 from	 89	 patients	219 
meeting	 the	 criteria	 established	 in	 the	 UK	 National	 Institute	 for	 Health	 and	 Care	220 
Excellence	 2008	 criteria	 were	 available.	 An	 additional	 cohort	 of	 62	 patients	 with	221 
diabetes	mellitus	but	without	proteinuria	or	other	evidence	of	DKD	were	included,	as	222 
were	 samples	 from	41	 people	without	 evidence	 of	 diabetes	 or	DKD	 (Table	 1).	We	223 
included	diabetes	patients	without	DKD	as	a	 third	group	 in	 this	analysis	 to	 identify	224 
DKD-specific	miRNA	detection	changes	and	not	purely	hyperglycaemia-driven	effects	225 
from	our	profiling	comparison	of	DKD	patients	with	control	individuals.	226 
	 Significant	 differences	were	 again	 seen	between	DKD	patients	 and	 controls	227 
for	 miR-126	 (2.8-fold	 increase;	 p<0.0001;	 Figure	 2A),	 miR-155	 (1.8-fold;	 p<0.001;	228 
Figure	2B)	and	miR-29b	(4.6-fold;	p	=	0.024;	Figure	2C).	Comparison	of	DKD	patients	229 
with	diabetic	patients	without	DKD	was	statistically	significant	for	miR-	126	(3.1-fold	230 
increase;	p<0.0001)	and	miR-155	(1.6-fold;	p	=	0.024)	with	a	trend	to	increased	miR-231 
29b	(4.1-fold;	p	=	0.121)	(Figure	2A-C).		232 
	 RT-qPCR	 data	 for	 all	 3	 miRNAs	 were	 used	 to	 compare	 DKD	 patients	 and	233 
diabetic	 patients	 without	 DKD	 in	 the	 combined	 receiver	 operating	 characteristic	234 
(ROC)	 curve	 analysis	 shown	 in	 Figure	 2D,	 giving	 an	 area	 under	 the	 curve	 (AUC)	 of	235 
0.80.	To	analyse	the	contributions	of	each	miRNA	to	the	above	ROC	curve,	individual	236 
specificity	 and	 likelihood	 ratios	were	 calculated	 for	 relative	 expression	 (RQ)	 values	237 
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equivalent	 to	 a	 sensitivity	 of	 80%.25,26	 Data	 displayed	 in	 Table	 2	 illustrate	 the	238 
magnitude	 of	 corresponding	 specificity	 values	 was	miR-126	 >	miR-155	 >	miR-29b,	239 
and	 that	 combined	 miRNA	 data	 resulted	 in	 a	 ≥6.5%	 increase	 in	 specificity	 and	240 
likelihood	ratio	compared	with	individual	miRNAs.	These	RQ	data	were	then	used	as	241 
consecutive	 threshold	 values	 to	 discriminate	 between	 DKD	 and	 diabetic	 patients	242 
without	DKD	(D	 in	Table	3)	 from	the	 independent	cohort.	The	discriminatory	order	243 
was	 miR-29b	 (DKD/D	 =	 5.62)	 >	 miR-126	 (3.48)	 >	 miR-155	 (2.23),	 and	 RQ	 values	244 
exceeding	all	3	thresholds	were	obtained	for	48.0%	of	DKD	patients	compared	with	245 
3.6%	of	diabetic	patients	without	DKD	(Table	3).	246 
	247 
Laser	capture	microdissection	shows	 increased	glomerular	abundance	of	miR-126	248 
and	miR-29b	that	is	replicated	in	GEnC	culture	249 
Previous	 reports	 have	 linked	 changes	 in	miRNA	 expression	 to	 DKD	 pathology,	 but	250 
have	 focused	 on	 whole	 tissue	 studies.	 For	 example,	 we	 showed	 association	 of	251 
decreased	miR-192	 expression	with	 disease	 progression	 in	 DKD	 biopsies	 by	 in	 situ	252 
hybridisation.13	253 
	 In	the	present	study	we	used	 laser	capture	microdissection	(LCM)	to	 isolate	254 
glomeruli,	 proximal	 and	 distal	 tubules	 (Figure	 3A)	 from	 histologically	 normal	255 
formalin-fixed,	 paraffin-embedded	 (FFPE)	 renal	 biopsy	 samples,	 and	 analysed	miR-256 
126,	 miR-155	 and	 miR-29b	 expression	 by	 RT-qPCR.	 In	 Figure	 3B,	 a	 typical	 CD10-257 
stained	 FFPE	 biopsy	 section	 is	 seen	 before	 and	 after	 LCM	 to	 isolate	 glomeruli,	258 
proximal	and	distal	renal	tubules.	MiR-126,	miR-155	and	miR-29b	were	detected	 in	259 
extracts	 from	 all	 three	 nephron	 regions	 (Figure	 3,	 C-E).	 Increased	 glomerular	260 
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abundances	were	observed	 for	miR-126	 (Figure	3C)	and	miR-29b	 (Figure	3E),	while		261 
miR-155	was	most	abundant	in	the	distal	tubule	(Figure	3D).	262 
	 Conclusions	 regarding	 nephron	 region-specific	 miRNA	 expression	 from	 the	263 
above	analyses	are	 inherently	 limited,	however,	since	tissue	extracts	are	subject	to	264 
trace	contamination	by	cells	from	other	nephron	domains.	Therefore,	cellular	miRNA	265 
localisation	within	each	nephron	 region	was	 subsequently	 investigated	by	RT-qPCR	266 
analysis	of	podocyte	and	endothelial	cell	(GEnC)	cultures	from	the	glomerulus,	renal	267 
proximal	 tubular	 epithelial	 cells	 (PTC)	 and	 fibroblasts.	 Detection	 of	 miR-126	 was	268 
significantly	higher	 in	GEnCs	compared	with	other	cell	 types	(Figure	3F).	Most	miR-269 
155	was	detected	 in	PTCs	and	 least	 in	GEnCs	 (Figure	3G),	while	miR-29b	was	most	270 
abundant	in	GEnCs	(Figure	3H).	271 
	272 
GEnC	 release	 of	miR-126	 and	miR-29b	 in	 an	 in	 vitro	model	 of	 hyperglycaemia	 is	273 
driven	by	TNF-α	and	TGF-β1,	respectively	274 
The	 above	 data	 localized	 the	majority	 of	 miR-126	 and	miR-29b	 expression	 to	 the	275 
GEnC.	We	 next	 sought	 stimuli	 by	 which	miRNAs	 are	 released	 into	 the	 glomerular	276 
ultrafiltrate,	 and	 hence	 the	 urine.	 Data	 from	 animal	 models	 of	 diabetes	 show	277 
increased	glomerular	and	PTC	TNF-α	expression,	and	renoprotective	effects	of	TGF-β	278 
inhibitors	 have	 also	 been	 reported.27,28	 GEnC	 expression	 of	 our	 candidate	miRNAs	279 
was	thus	analysed	in	vitro	in	response	to	TNF-α	and	TGF-β1	in	normoglycaemia	and	280 
hyperglycaemia	(Figure	4,	A-F).	281 
	 The	 presence	 of	 TNF-α	 led	 to	 significantly	 increased	 miR-126	 detection	 in	282 
GEnC	conditioned	medium	at	5	mM	and	25	mM	D-glucose	(Figure	4B),	a	pattern	also	283 
seen	 for	 miR-29b	 following	 TGF-β1	 addition	 (Figure	 4D).	 These	 cytokines	 did	 not	284 
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increase	GEnC	expression	of	miR-126	(Figure	4A),	or	miR-29b	(Figure	4C),	a	pattern	285 
consistent	with	increased	release,	but	not	expression,	of	miRNAs.	286 
	 No	significant	changes	in	miR-155	were	detected	in	response	to	elevated	D-287 
glucose	 with	 either	 cytokine,	 and	 data	 for	 TNF-α	 are	 shown	 (Figure	 4,	 E	 and	 F).	288 
Similarly,	 changes	 in	 miR-126	 following	 TGF-β1	 addition,	 and	 for	 miR-29b	 in	 the	289 
presence	of	TNF-α,	were	not	observed	 (data	not	shown).	Elevated	D-glucose	alone	290 
did	not	change	miRNA	expression	in	GEnCs	or	conditioned	medium	(Figure	4,	A-F).	291 
	 	292 
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Discussion	293 
Diabetic	kidney	disease	 (DKD)	 is	 the	 leading	cause	of	kidney	 failure	 requiring	 renal	294 
replacement	 therapy	 worldwide,	 but	 effective	 methods	 to	 identify	 and	 halt	295 
progression	 of	 disease-specific	 pathophysiological	 changes	 remain	 elusive.	 Current	296 
effective	 interventions	 such	 as	 control	 of	 blood	 glucose	 and	 blood	 pressure	 are	297 
challenging	 to	 achieve,	 costly	 and	 time	 intensive.	 Existing	 tests	 track	 DKD	 from	298 
diabetic	 diagnosis	 to	 kidney	 failure,	 but	 do	 not	 allow	 accurate	 prognosis	 for	 the	299 
individual	 patient.	 In	 addition,	 the	 absence	 of	 treatment	 response	 biomarkers	300 
hinders	development	of	emerging	DKD	therapies.	There	 is	 thus	an	unmet	need	 for	301 
additional	DKD	biomarkers	to	target	intervention	and	follow	response	to	therapy.	302 
	 In	this	study	we	set	out	to	identify	urinary	miRNA	DKD	biomarkers.	Increased	303 
detection	 of	 miR-126,	 miR-155	 and	 miR-29b	 was	 observed	 in	 the	 urine	 of	 DKD	304 
patients	 in	 comparison	 with	 both	 unaffected	 individuals	 and	 diabetic	 patients	305 
without	 DKD.	 MiRNA	 localization	 and	 release	 studies	 further	 suggested	 specific	306 
release	of	miR-126	and	miR-29b	from	GEnCs.	This	raised	the	possibility	that	urinary	307 
miRNA	quantification	might	provide	data	on	ongoing	pathological	processes,	and	so	308 
aid	patient	stratification	and	measurement	of	response	to	therapy.	309 
	 Urinary	miRNA	biomarkers	have	several	potential	significant	advantages	over	310 
circulating	miRNAs	for	adoption	into	existing	treatment	pathways	alongside	current	311 
biomarkers,	including	speed	and	cost	of	non-invasive	sample	access.29	However,	few	312 
urinary	miRNA	DKD	biomarker	data	have	so	far	been	reported.	Previous	studies	have	313 
focused	on	circulating	miRNAs,	and	have	generated	conflicting	data	with	respect	to	314 
association	of	miR-126	with	diabetes	mellitus	and/or	DKD.	A	 recent	cross-sectional	315 
analysis	 of	 type	 2	 diabetes	 mellitus	 patients	 found	 a	 negative	 association	 with	316 
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plasma	 miR-126,30	 and	 similar	 findings	 have	 been	 reported	 for	 type	 1	 diabetes	317 
mellitus	 and	 all	 complications.31	 By	 contrast,	miR-126	 detection	 did	 not	 change	 in	318 
whole	 blood	 from	 type	 2	 diabetes	 mellitus	 patients	 and	 control	 subjects,	 but	319 
decreased	in	DKD	patient	samples.32	Furthermore,	no	change	in	plasma	miR-126	was	320 
observed	in	a	study	of	paediatric	type	1	diabetic	patients.33	These	analyses	provide	321 
inconsistent	data	for	the	biomarker	utility	of	circulating	miR-126,	 in	contrast	to	the	322 
significant	and	reproducible	increases	we	detected	in	miR-126,	miR-155	and	miR-29b	323 
in	DKD	patient	urine	in	the	present	study.	324 
	 The	DKD-specific	alterations	in	urinary	miRNA	profiles	detected	in	this	study	325 
may	have	 functional	 significance.	Our	 in	 vitro	 analyses	 localized	miR-126	 and	miR-326 
29b	principally	 to	 the	GEnC,	with	miR-155	expression	distributed	evenly	across	 the	327 
nephron.	Glomerular	endothelial	localization	of	miR-126	may	reflect	the	role	of	this	328 
transcript	 in	 vascular	 regulation.	 Targeted	 mouse	 miR-126	 deletion	 resulted	 in	329 
vascular	 abnormalities	 by	 removing	 inhibition	 of	 sprouty-related	 EVH1	 domain-330 
containing	 protein	 1	 expression,	 thereby	 enhancing	 vascular	 endothelial	 growth	331 
factor	 (VEGF)	 function.34	 A	 role	 in	 DKD	 pathology	 for	 VEGFA	 signalling	 between	332 
GEnCs	 and	 podocytes	 has	 been	 proposed.35	 In	 addition,	 miR-126	 repression	 of	333 
vascular	 cell	 adhesion	 molecule	 1	 expression	 in	 human	 umbilical	 vein	 endothelial	334 
cells	 regulates	 their	 response	 to	 pro-inflammatory	 adhesion	molecules.36	MiR-126	335 
has	 also	 been	 implicated	 in	 the	 heterogenic	 inflammatory	 response	 of	 renal	336 
microvascular	endothelial	cells.37	337 
	 Increased	 expression	 of	 miR-155	 has	 been	 observed	 in	 DKD	 patient	 renal	338 
biopsies,	 in	 close	 correlation	with	 increased	 serum	creatinine.38	 Furthermore,	miR-339 
155	deficiency	attenuated	renal	damage	and	IL-17	expression	was	downregulated	in	340 
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streptozotocin-induced	 DKD	 mice.39	 Together	 with	 miR-126,	 miR-155	 has	 been	341 
implicated	 in	 multiple	 forms	 of	 vascular	 remodelling	 and	 associated	 with	342 
cardiovascular	disease.40	343 
	 Decreased	miR-29b	has	been	reported	in	early	and	advanced	animal	models	344 
of	diabetic	renal	fibrosis.41	Chen	and	colleagues	found	that	loss	of	renal	miR-29b	in	345 
db/db	 mice	 led	 to	 increased	 albuminuria,	 TGF-β-mediated	 fibrosis	 and	 immune	346 
injury,	while	restored	miR-29b	expression	inhibited	renal	injury.	42		Indeed,	while	we	347 
have	 focused	 on	 upregulated	miRNAs	 in	 this	 study,	we	 acknowledge	 the	 potential	348 
importance	of	miRNA	downregulations	that	we	detected.	349 
	 In	 the	 present	 study	we	 localized	miR-29b	 to	 the	 glomerular	 endothelium.	350 
Reduction	of	collagen	and	laminin	synthesis	has	been	reported	following	forced	miR-351 
29b	expression	in	human	corneal	endothelial	cells.43	In	apoE	knockout	mice,	miR-29b	352 
induced	aortic	endothelial	permeability	 in	 response	 to	a	high	 fat	diet,	and	brought	353 
about	aortic	apoptosis	by	direct	targeting	of	melatonin	receptor	mt1.44	 In	addition,	354 
upregulated	 miR-29b	 expression	 has	 been	 observed	 in	 human	 umbilical	 vein	355 
endothelial	cells	exposed	to	hyperglycaemia.45	356 
	 The	 cytokine-driven	 release	 from	GEnCs	 observed	 for	miR-126	 (TNF-α)	 and	357 
miR-29b	 (TGF-β1)	 reported	 here	 suggests	 that	 these	 cells	 may	 be	 the	 principal	358 
source	of	elevated	urinary	miR-126	and	miR-29b	detected	in	DKD.	We	speculate	that	359 
this	constitutes	evidence	for	disease-related	signalling	down	the	nephron	that	will	be	360 
interesting	 to	 test	 in	 future	 studies.	 Indeed,	we	 have	 demonstrated	 association	 of	361 
urinary	 miRNAs	 with	 exosomes10	 and	 exosomal	 transport,	 which	 might	 facilitate	362 
passage	of	miRNAs	through	the	nephron,	has	been	reported	for	all	three	candidate	363 
biomarker	miRNAs.	364 
 19	
	 Exosome-mediated	 release	 of	 miR-126	 from	 CD34+	 peripheral	 blood	365 
mononuclear	 cells	 is	 proangiogenic,	 and	 decreased	 miR-126	 was	 detected	 in	366 
elevated	glucose	cell	culture	and	diabetic	patients.46	MiR-155	is	depleted	in	urinary	367 
exosomes	 from	microalbuminuric	 type	 1	 diabetes	mellitus	 patients.47	 Endogenous	368 
miR-29b,	 spontaneously	 released	 from	beta-cells	within	exosomes,	 stimulates	TNF-369 
 α	secretion	from	spleen	cells	isolated	from	diabetes-prone	NOD	mice	in	vitro.48	370 
	 In	summary,	we	have	used	unbiased	profiling	approaches	to	identify	a	urinary	371 
miRNA	signature	associated	with	DKD,	and	have	subsequently	confirmed	 increased	372 
miR-126,	miR-155	and	miR-29b	in	an	independent	patient	cohort.	MiR-126	and	miR-373 
29b	were	identified	as	enriched	in	GEnCs,	and	released	from	these	cells	in	response	374 
to	 DKD-related	 cytokines.	 Urinary	 miR-126,	 miR-155	 and	 miR-29b	 are	 therefore	375 
promising	 DKD	 biomarkers,	 and	 the	 potential	 pathological	 significance	 of	miR-126	376 
and	miR-29b	release	from	GEnCs	merits	further	evaluation.	377 
	 	378 
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Figure	legends	555 
Figure	 1	Urinary	miRNA	detection	 in	urine	 samples	 from	DKD	patients	and	control	556 
subjects.	A:	Volcano	plot	showing	the	detection	profile	of	the	377	urinary	miRNAs	in	557 
TLDA	Card	A	in	DKD	patients	(n	=	20;	four	pools	of	five	patients)	and	controls	(n	=	20;	558 
four	pools	of	five	controls).	The	dotted	horizontal	line	represents	a	p	value	boundary	559 
of	 0.05.	 B:	 Fold	 change	 of	 miRNA	 detection	 between	 DKD	 patients	 and	 controls.	560 
DataAssist	 Software	 (Thermo	 Fisher	 Scientific)	 was	 used	 to	 perform	 relative	561 
quantification	for	sample	comparison,	to	perform	t-test	sample	group	comparisons,	562 
and	to	produce	the	graphic	output	shown.	 (C-E)	RT-qPCR	analysis	shows	significant	563 
differences	 in	 detection	 of	 (C)	 miR-126,	 (D)	 miR-155	 and	 (E)	 miR-29b	 between	564 
patients	 and	 control	 urine	 in	 the	 component	 urine	 samples	 pooled	 for	 profiling	565 
analyses	(A	and	B).	DKD	patients	versus	controls	for	C:	miR-126,	D:	miR-155,	E:	miR-566 
29b	(n	=	20	for	each	group).	Analysis	was	carried	out	by	unpaired	2-tailed	t-test	with	567 
Welch’s	correction.	Profiling	data	analysis	using	the	NormFinder	algorithm	identified	568 
miR-191	as	optimal	for	normalisation	of	our	RT-qPCR	data.	Data	were	normalized	to	569 
endogenous	control	miR-191	and	are	presented	as	mean	+/-	SEM.	**P	<	0.01,	***P	<	570 
0.005	and	*****P	<	0.0005.	571 
	572 
Figure	 2	 RT-qPCR	 detection	 of	 selected	 miRNAs	 in	 patients	 and	 control	 subjects.	573 
Relative	expression	was	significantly	different	in	89	DKD	patients	compared	with	62	574 
diabetic	patients	without	DKD	and	41	controls	for	(A)	miR-126	and	(B)	miR-155,	and	575 
significantly	 different	 in	 DKD	 patients	 compared	 with	 controls	 for	 (C)	 miR-29b.	 A:	576 
DKD	patients	versus	diabetic	patients	without	DKD	and	controls;	B:	DKD	patients	and	577 
diabetic	patients	without	DKD;	DKD	patients	versus	controls;	C:	DKD	patients	versus	578 
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controls	 (n	 =	 89	 DKD	 patients,	 62	 diabetic	 patients	 without	 DKD,	 41	 controls).	579 
Analysis	 was	 carried	 out	 by	 unpaired	 1-tailed	 t-test	 with	Welch’s	 correction.	 Data	580 
were	 normalized	 to	 endogenous	 control	 miR-191	 and	 are	 presented	 as	 mean	 +/-	581 
SEM.	(D)	Combined	receiver	operating	characteristic	curve	analysis	for	miR-126,	miR-582 
155	and	miR-29b,	area	under	the	curve	(AUC)	=	0.80.	Data	were	generated	using	the	583 
pROC	package	in	R-3.2.3.	*P	<	0.05,	****P	<	0.001	and	******P	<	0.0001.	584 
	585 
Figure	 3	 Localization	 of	miRNA	 expression	 by	 laser	 capture	microdissection	 (LCM)	586 
and	cell	culture.	A:	Key	functional	nephron	domains	include	the	glomerulus	(G),	the	587 
proximal	tubule	(PT)	and	the	distal	tubule	(DT).	B:	A	CD10-stained	FFPE	renal	biopsy	588 
sample	before	and	after	excision	of	glomeruli	by	LCM.	Bars	=	100	µm.	(C-E)	Relative	589 
expression	of	miR-126,	miR-155	and	miR-29b,	 respectively,	 in	LCM-isolated	Gs,	PTs	590 
and	DTs	from	5	renal	biopsies	of	healthy	individuals.	C:	G	versus	PT;	G	versus	DT	(n	=	591 
5	biopsies).	(F-H)	Relative	expression	of	miR-126,	miR-155	and	miR-29b,	respectively,	592 
in	 in	 vitro	 cultured	 HK-2	 renal	 proximal	 tubular	 epithelial	 cells	 (PTCs),	 fibroblasts,	593 
podocytes	 and	 conditionally	 immortalized	 glomerular	 endothelial	 cells	 (GEnCs).	 F:	594 
GEnCs	versus	fibroblasts;	GEnCs	versus	PTCs	and	podocytes;	G:	PTC	versus	GEnCs;	H:	595 
GEnCs	versus	podocytes	(n	=	4).	Analysis	was	carried	out	by	one-way	ANOVA	analysis	596 
with	Tukey’s	multiple	comparison	test.	Data	were	normalized	to	endogenous	control	597 
miR-191	 and	 are	 presented	 as	mean	 +/-	 SEM.	 *P	 <	 0.05,	 **P	 <	 0.01	 and	 ****P	 <	598 
0.001.	599 
	600 
	601 
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Figure	4	MiRNA	expression	in	GenCs	and	GenC	conditioned	medium	in	response	to	602 
hyperglycaemia	 and	 DKD-related	 cytokines.	 Following	 24	 h	 culture	 in	 5	mM	or	 25	603 
mM	 D-glucose,	 relative	 expression	 in	 GEnCs	 and	 GEnC	 conditioned	 medium,	604 
respectively,	of	(A	and	B)	miR-126	in	response	to	10	ng/ml	TNF-α,	(C	and	D)	miR-29b	605 
in	response	to	1	ng/ml	TGF-β1	and	(E	and	F)	miR-155	in	response	to	10	ng/ml	TNF-α,	606 
and	in	untreated	cells.	B:	5	mM	D-glucose	versus	5	mM	D-glucose	plus	TNF-α,	and	25	607 
mM	D-glucose	versus	25	mM	D-glucose	plus	TNF- α;	C:	5	mM	D-glucose	versus	5	mM	608 
D-glucose	plus	TGF-β1,	and	25	mM	D-glucose	versus	25	mM	D-glucose	plus	TGF-β1;	609 
D:	5	mM	D-glucose	versus	5	mM	D-glucose	plus	TGF-β1;	25	mM	D-glucose	versus	25	610 
mM	 D-glucose	 plus	 TGF-β1	 (n	 =	 4).	 Analysis	 was	 carried	 out	 by	 one-way	 ANOVA	611 
analysis	 with	 Tukey’s	 multiple	 comparison	 test.	 Data	 were	 normalized	 to	612 
endogenous	control	miR-191	and	are	presented	as	mean	+/-	SEM.	*P	<	0.05	and	**P	613 
<	0.01.	614 
	615 
	616 
	617 
	618 
	619 
	620 
	621 
	622 
	623 
	624 
	625 
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Table	 1	Demographic	and	clinical	parameters	of	patients	 recruited	 from	2	centres:	626 
Wales	 Kidney	 Research	 Tissue	 Bank,	 Cardiff	 (University	 Hospital	 Wales)	 and	627 
Birmingham	 (University	Hospital	 Birmingham,	 Renal	 Impairment	 in	 Secondary	 care	628 
(RIISC)	study	cohort)	(n	=	151)	629 
	630 
	
Feature	
Patients	
(n=151)	
	
Diabetic	
(n=62)	
DKD	
(n=89)	
Controls	
(n=41)	
Male	n	(%)	 37	(58)	 55	(62)	 18	(44)	
Non-Caucasian	n	(%)	 13	(21)	 33	(37)	 	
Mean	Age	(years,	SD)	 52	+/-	16.1	 62	+/-	13.6	 55	+/-	15.4	
		 	 	 	
eGFR	ml/min/1.73m2	 	 	 	
Mean	(SD)	 78	+/-16.3	 30	+/-	20.9	 	
Median	(IQR)	 84	(72-90)	 22	(17-38)	 	
		 	 	 	
CKD	stage	n(%)	 	 	 	
No	CKD/CKD	G1	(eGFR	≥	90)	 23	(37)	 2	(2)	 	
CKD	G2	(eGFR	=	60-89)	 32	(52)	 10	(11)	 	
CKD	G3	(eGFR	=	30-59)	 5	(8)	 17	(19)	 	
CKD	G4	(eGFR	=	15-29)	 2	(3)	 45	(51)	 	
CKD	G5	(eGFR	<15)	 0	 15	(17)	 	
		 	 	 	
ACR*	mg/mmol	n(%)	 	 	 	
A1-Normal-high	normal	(ACR<3)	 54	(87.1)	 15	(16.9)	 	
A2-Moderately	increased	(ACR	3-30)	 8	(12.9)	 25	(28.1)	 	
A3-Severely	increased	(ACR>30)	 0	(0)	 49	(55.0)	 	
	 	 	 	
*Albumin:Creatinine	 ratio	 (ACR)	 group	 cut-offs	 and	 nomenclature	 derived	 from	631 
KDIGO	2012	recommendations.	632 
	633 
	634 
	635 
 32	
Table	2	Specificity	values,	likelihood	ratios	and	RQ	thresholds	for	miR-126,	miR-155,	636 
miR-29b	and	all	three	miRNAs	above	an	80%	ROC	curve	sensitivity	threshold	637 
	638 
	
Sensitivity	
(%)	
Specificity	
(%)	
Likelihood	
Ratio	
RQ	
Threshold	
3	miRNAs	 80.21	 63.64	 2.206	 >	1.148	
miR-126	 80.41	 57.14	 1.876	 >	0.6762	
miR-155	 80.61	 52.00	 1.679	 >	0.9110	
miR-29b	 80.61	 40.00	 1.344	 >	0.8058	
	639 
Table	3	DKD	and	diabetic	patients	without	DKD	(D)	patient	numbers	and	percentages	640 
above	an	80%	ROC	curve	sensitivity	threshold	for	miR-126,	miR-155,	miR-29b	and	all	641 
three	miRNAs	642 
	643 
Patients	above	80%	sensitivity	threshold	
																							miR-126								miR-155						miR-29b								3	miRNAs								Total	
D	 23	 30	 13	 2	 55	
DKD	 80	 67	 73	 47	 98	
Percentage	of	patients	above	80%	sensitivity	threshold	
																					miR-126								miR-155						miR-29b								3	miRNAs		
D	 41.8	 54.6	 23.6	 3.6	 	
DKD	 81.6	 68.4	 74.5	 48.0	 	
	644 
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